ABIO

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.